ImmunoPrecise Antibodies Ltd. (IPA): Price and Financial Metrics

ImmunoPrecise Antibodies Ltd. (IPA): $2.07

0.02 (-0.96%)

POWR Rating

Component Grades








Add IPA to Watchlist
Sign Up

Industry: Biotech




#108 of 374

in industry

IPA Price/Volume Stats

Current price $2.07 52-week high $5.90
Prev. close $2.09 52-week low $1.70
Day low $1.95 Volume 14,182
Day high $2.14 Avg. volume 58,475
50-day MA $2.24 Dividend yield N/A
200-day MA $3.35 Market Cap 51.85M

IPA Stock Price Chart Interactive Chart >


  • IPA scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.25% of US stocks.
  • IPA's strongest trending metric is Stability; it's been moving up over the last 177 days.
  • IPA's current lowest rank is in the Quality metric (where it is better than 5.65% of US stocks).

IPA Stock Summary

  • IMMUNOPRECISE ANTIBODIES LTD's stock had its IPO on December 31, 2020, making it an older stock than merely 10.13% of US equities in our set.
  • With a year-over-year growth in debt of 178.99%, IMMUNOPRECISE ANTIBODIES LTD's debt growth rate surpasses 93.75% of about US stocks.
  • The volatility of IMMUNOPRECISE ANTIBODIES LTD's share price is greater than that of 85.54% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to IPA, based on their financial statements, market capitalization, and price volatility, are LEU, CSGS, SOFO, NTGR, and INTZ.
  • Visit IPA's SEC page to see the company's official filings. To visit the company's web site, go to

IPA Price Target

For more insight on analysts targets of IPA, see our IPA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $16.17 Average Broker Recommendation 1.5 (Moderate Buy)

ImmunoPrecise Antibodies Ltd. (IPA) Company Bio

ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.

IPA Latest News Stream

Event/Time News Detail
Loading, please wait...

IPA Latest Social Stream

Loading social stream, please wait...

View Full IPA Social Stream

Latest IPA News From Around the Web

Below are the latest news stories about IMMUNOPRECISE ANTIBODIES LTD that investors may wish to consider to help them evaluate IPA as an investment opportunity.

ImmunoPrecise Antibodies Announces CFO Transition

VICTORIA, British Columbia, September 19, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), today announced that it has accepted the resignation of Brad McConn, CFO, effective September 29, 2023. IPA has named Kristin Taylor, MBA, CPA, as interim Chief Financial Officer.

Yahoo | September 19, 2023

IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024

VICTORIA, British Columbia, September 14, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2024, which ended July 31, 2023.

Yahoo | September 14, 2023

IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023

VICTORIA, British Columbia, September 08, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2024, on Thursday, September 14, 2023, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call.

Yahoo | September 8, 2023

IPA Announces Board Refreshment

VICTORIA, British Columbia, September 05, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company.

Yahoo | September 5, 2023

IPA Responds to 13D Filing

VICTORIA, British Columbia, August 09, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today issued the following statement in response to the Schedule 13D filing made on July 7, 2023 by Ingalls & Snyder, LLC a New York-based investment manager.

Yahoo | August 9, 2023

Read More 'IPA' Stories Here

IPA Price Returns

1-mo -0.48%
3-mo -34.81%
6-mo -30.07%
1-year -58.60%
3-year -77.67%
5-year N/A
YTD -60.27%
2022 -2.80%
2021 -64.15%
2020 579.08%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!